Last updated: September 3, 2026
Ertugliflozin/metformin hydrochloride, marketed in the U.S. as Segluromet by Merck and Pfizer, is a fixed-dose combination for adults with type 2 diabetes. Its commercial position is constrained by intense SGLT2 competition, generic metformin, limited differentiation versus other SGLT2/metformin combinations, and the absence of separately disclosed product revenue. The combination remains commercially relevant through the late 2020s, but its long-term value depends on the residual ertugliflozin patent estate and the ability to defend market share against Jardiance, Farxiga, Invokana, and generic substitution.
What is ertugliflozin/metformin hydrochloride and how does it work?
Segluromet combines two oral antihyperglycemic agents:
| Component |
Mechanism |
Commercial status |
| Ertugliflozin |
Selective sodium-glucose cotransporter 2, or SGLT2, inhibitor that increases urinary glucose excretion |
Branded, patent-protected molecule |
| Metformin hydrochloride |
Reduces hepatic glucose production and improves insulin sensitivity |
Long-established generic drug |
The U.S. Food and Drug Administration approved Segluromet in December 2017 as an adjunct to diet and exercise for adults with type 2 diabetes whose glycemic control is inadequate on ertugliflozin or metformin, or for patients already receiving both agents separately.[1]
The product is available in two strengths:
| Strength |
Ertugliflozin |
Metformin hydrochloride |
| Lower dose |
2.5 mg |
500 mg or 1,000 mg, depending on presentation |
| Higher dose |
7.5 mg |
500 mg or 1,000 mg, depending on presentation |
The combination is intended to simplify treatment for patients requiring both mechanisms. It does not create a new therapeutic class and does not remove the need for monitoring renal function, volume status, genital infections, ketoacidosis risk, and metformin-associated lactic acidosis risk.
What is the FDA regulatory status of Segluromet?
Segluromet has FDA approval under New Drug Application 209806. Its active ingredient, ertugliflozin, is also marketed as Steglatro, while the ertugliflozin/sitagliptin combination is marketed as Steglujan.[1]
FDA product portfolio
| Product |
Active ingredients |
U.S. approval timing |
Strategic role |
| Steglatro |
Ertugliflozin |
December 2017 |
Ertugliflozin monotherapy |
| Segluromet |
Ertugliflozin/metformin HCl |
December 2017 |
Fixed-dose combination |
| Steglujan |
Ertugliflozin/sitagliptin |
December 2017 |
Dual branded combination |
The FDA labeling identifies renal function as a central limitation. Segluromet is not recommended for initiation in patients with an estimated glomerular filtration rate below the labeled threshold, and dose selection depends on renal status. The label also includes warnings relating to ketoacidosis, lower-limb amputation risk, volume depletion, urosepsis, genital mycotic infections, hypoglycemia when used with insulin or insulin secretagogues, and metformin-associated lactic acidosis.[1]
What patents protect ertugliflozin and Segluromet?
The principal intellectual-property value is concentrated in ertugliflozin, not metformin hydrochloride. Metformin is generic and does not provide meaningful molecule-level exclusivity.
Pfizer and Merck developed ertugliflozin through a global collaboration. The relevant patent estate has historically covered the ertugliflozin chemical compound, pharmaceutical compositions, and related therapeutic use. Public regulatory and company disclosures place the key U.S. protection period in the late 2020s, with certain listed patent rights potentially extending into approximately 2029 or later depending on patent-term adjustment, patent-term extension, and the specific product claim.[2][3]
Patent categories
| Patent category |
Relevance to Segluromet |
Expected competitive effect |
| Ertugliflozin compound patents |
Protect the active SGLT2 inhibitor |
Main barrier to generic ertugliflozin |
| Composition and formulation patents |
May cover dosage forms or combinations |
Could delay specific fixed-dose generic products |
| Method-of-use patents |
May cover treatment of diabetes or dosing regimens |
Usually narrower litigation value than compound claims |
| Metformin patents |
Commercially irrelevant because metformin is generic |
Does not protect the combination independently |
| Manufacturing patents |
Could cover intermediates, processes, or crystalline forms |
May increase development and litigation cost |
A generic company can challenge a listed patent under Paragraph IV of the Hatch-Waxman Act. A Paragraph IV filing can trigger patent litigation and a 30-month stay of FDA approval if the branded sponsor sues within the statutory period.[4]
How strong is the patent estate for ertugliflozin?
The estate is materially stronger for ertugliflozin monotherapy and ertugliflozin-containing products than for the metformin component. Its commercial strength depends on three factors:
- Whether the core compound patent remains enforceable through the projected expiry period.
- Whether later-listed formulation or combination patents withstand validity and infringement challenges.
- Whether generic manufacturers can design around formulation or process claims while using the same active ingredient.
The principal risk is an early generic challenge to secondary patents. Secondary patents normally provide less protection than a valid compound patent because they may be vulnerable to obviousness, written-description, enablement, or non-infringement arguments.
When does ertugliflozin lose exclusivity?
The effective U.S. loss-of-exclusivity window is expected to fall in the late 2020s, subject to the specific Orange Book patents, patent-term adjustments, pediatric exclusivity, and litigation outcomes.
| Exclusivity element |
Estimated timing or status |
| FDA approval |
December 2017 |
| New chemical entity exclusivity |
Expired in 2022 |
| Orphan-drug exclusivity |
Not applicable |
| Patent-protected commercial period |
Expected to run into approximately 2029 or later |
| Generic entry |
Dependent on Paragraph IV filings, litigation, and final approval |
| Metformin component |
Already generic |
The five-year new chemical entity exclusivity associated with ertugliflozin expired before the expected patent expiry period. Patent rights, rather than regulatory exclusivity, now determine the primary U.S. entry barrier.[1][4]
The exact first-launch date for a generic Segluromet equivalent cannot be inferred solely from the end date of regulatory exclusivity. A generic applicant may obtain approval after resolving patent litigation, receiving a court judgment, entering a settlement, or waiting for listed patents to expire.
What is the Orange Book status of Segluromet?
Segluromet is an FDA-approved prescription drug subject to Orange Book patent listing. The Orange Book is the operative U.S. reference for listed patents, patent-use codes, therapeutic equivalence determinations, and generic approval pathways.[5]
The Orange Book distinction matters because Segluromet contains both a branded active ingredient and a generic active ingredient. A future abbreviated new drug application would need to address patents listed against the reference product. A manufacturer could also pursue separate ertugliflozin and metformin products rather than a fixed-dose combination, which would create a different regulatory and commercial pathway.
The strategic exposure is therefore divided:
- Generic metformin is available now.
- Generic ertugliflozin depends on patent and regulatory resolution.
- A generic fixed-dose Segluromet product must address both formulation and combination-product requirements.
- Physicians and payers may substitute separate generic components even before a fully substitutable fixed-dose product becomes available.
Which companies challenge or compete with ertugliflozin?
The principal competitive pressure comes from other SGLT2 inhibitors, not from direct generic competition today.
| Product |
Company |
Position relative to ertugliflozin |
| Jardiance |
Boehringer Ingelheim and Eli Lilly |
Leading SGLT2 franchise with strong cardiovascular and heart-failure positioning |
| Farxiga |
AstraZeneca |
Broad diabetes, heart-failure, and chronic kidney disease positioning |
| Invokana |
Johnson & Johnson |
Earlier SGLT2 entrant with established class recognition |
| Steglatro |
Merck and Pfizer |
Same active ingredient as Segluromet |
| Xigduo XR |
AstraZeneca |
Dapagliflozin/metformin fixed-dose combination |
| Synjardy |
Boehringer Ingelheim and Eli Lilly |
Empagliflozin/metformin fixed-dose combination |
| Invokamet |
Johnson & Johnson |
Canagliflozin/metformin fixed-dose combination |
Ertugliflozin entered the market after Jardiance, Farxiga, and Invokana had established payer access, prescriber familiarity, and outcome data. That timing reduced the probability that Segluromet would become a leading SGLT2/metformin combination.
How does Segluromet compare with Synjardy and Xigduo XR?
Segluromet competes primarily on class access and dosing convenience. It has fewer commercial advantages in cardiovascular and renal positioning than the leading alternatives.
| Factor |
Segluromet |
Synjardy |
Xigduo XR |
| SGLT2 ingredient |
Ertugliflozin |
Empagliflozin |
Dapagliflozin |
| Metformin |
Yes |
Yes |
Yes |
| Cardiovascular evidence |
VERTIS-CV demonstrated cardiovascular safety, but not the same level of broad outcome leadership as Jardiance |
Strong cardiovascular and heart-failure profile for empagliflozin |
Strong heart-failure and kidney-disease positioning for dapagliflozin |
| Market entry |
Later |
Earlier |
Earlier |
| Generic metformin competition |
High |
High |
High |
| Brand differentiation |
Limited |
Stronger outcome-driven differentiation |
Stronger outcome-driven differentiation |
In VERTIS-CV, ertugliflozin met the primary cardiovascular safety objective but did not demonstrate superiority for the primary composite cardiovascular outcome.[6] That result limited the ability of ertugliflozin to compete on outcomes-based prescribing against Jardiance and Farxiga.
What is the financial trajectory for ertugliflozin and Segluromet?
Public financial reporting does not generally disclose Segluromet revenue as a standalone line item. Pfizer and Merck report broader collaboration, alliance, or portfolio figures rather than a detailed global revenue series for each ertugliflozin product.[2][3]
Commercial trajectory
| Period |
Commercial development |
Financial implication |
| 2017 to 2019 |
U.S. launch of Steglatro, Segluromet, and Steglujan |
Initial investment phase with launch costs and formulary development |
| 2020 to 2022 |
SGLT2 class expanded into heart failure and kidney disease |
Competitive gap widened against Jardiance and Farxiga |
| 2023 to 2024 |
Mature branded market with strong class competition |
Product remains commercially viable but lacks leading-class scale |
| 2025 to late 2020s |
Pre-LOE period |
Revenue depends on payer access, price discipline, and franchise retention |
| Post-LOE |
Potential generic entry |
Rapid price erosion and declining branded revenue risk |
The absence of separately reported revenue prevents a reliable product-level compound annual growth rate or precise revenue forecast. The economic profile can still be assessed:
- The active pharmaceutical ingredient has a branded price premium over metformin.
- Fixed-dose packaging can support adherence and preserve some value.
- The product faces internal substitution among Steglatro, Segluromet, and Steglujan.
- The franchise is exposed to class-level rebate competition.
- Market share is vulnerable where payers prefer Jardiance or Farxiga because of cardiovascular, heart-failure, or renal indications.
- Revenue is likely to decline sharply after generic ertugliflozin entry unless the companies retain protected formulations or achieve durable contracting advantages.
What revenue exposure exists before generic entry?
Revenue exposure is concentrated in the broader ertugliflozin franchise rather than Segluromet alone. The relevant products are:
- Steglatro monotherapy.
- Segluromet with metformin.
- Steglujan with sitagliptin.
This portfolio creates some lifecycle-management value because the same active ingredient is sold in multiple dosage forms. It also creates a common patent vulnerability. A successful generic challenge to core ertugliflozin patents could affect all three products.
The combination with metformin may face earlier commercial pressure from separate-product substitution. Payers can encourage use of generic metformin alongside branded ertugliflozin, reducing the incremental value of the fixed-dose product before formal generic Segluromet entry.
What generic launch scenarios exist for Segluromet?
Scenario 1: Delayed entry after core patent expiry
A generic sponsor waits for the principal ertugliflozin patent rights to expire and launches an approved equivalent. This is the lowest-litigation pathway but produces the latest entry date.
Scenario 2: Paragraph IV challenge
A generic applicant certifies that listed patents are invalid, unenforceable, or not infringed. If the sponsor sues, FDA approval may be stayed for up to 30 months unless litigation resolves earlier.[4]
Scenario 3: Separate-component substitution
Generic metformin is paired with branded or eventually generic ertugliflozin. This can erode Segluromet volume without direct fixed-dose generic substitution.
Scenario 4: Authorized generic or settlement launch
The originator or a licensee could launch an authorized generic, or a settlement could establish an agreed entry date. No widely reported public settlement should be treated as controlling without review of current court dockets and FDA records.
What manufacturing and intellectual-property barriers affect ertugliflozin?
Ertugliflozin manufacturing may require control of stereochemistry, intermediates, impurity profiles, solid-state properties, and scalable crystallization. These technical requirements can delay generic development even after the core composition patent expires.
The barriers are lower for metformin, which has a mature global supply base and extensive generic manufacturing experience. The more significant development burden lies in reproducing the ertugliflozin active ingredient and demonstrating bioequivalence in the fixed-dose combination.
Manufacturing patents can support commercial leverage if they cover a process that is difficult to design around. They are less effective when alternative synthetic routes are available and can be validated without infringing the claimed process.
What licensing deals affect ertugliflozin?
Ertugliflozin was developed through a collaboration between Pfizer and Merck. The companies jointly commercialized Steglatro, Segluromet, and Steglujan in a number of markets.[2][3]
The collaboration has two financial consequences:
- Product economics are divided between the partners rather than retained by a single originator.
- Commercial underperformance affects alliance economics across the full ertugliflozin portfolio.
The public financial disclosures of the partners do not provide enough product-level detail to calculate the exact split of Segluromet net sales, royalty burden, or contribution margin.
What litigation and settlement risks affect ertugliflozin?
The principal litigation risk is a Hatch-Waxman challenge to Orange Book-listed ertugliflozin patents. Potential claims include:
- Invalidity of compound or formulation claims.
- Non-infringement based on a proposed generic formulation.
- Lack of enforceability because of prosecution conduct.
- Patent-term disputes.
- Disputes over whether a patent is properly listed for the reference product.
No specific Paragraph IV lawsuit or settlement should be treated as active without a current review of federal court filings, FDA records, and the latest Orange Book edition. The commercial planning assumption remains that late-2020s patent expiry creates the first major generic-entry window.
Does biosimilar risk apply to ertugliflozin/metformin?
No. Biosimilar risk does not apply because Segluromet is a small-molecule drug, not a biologic. Competition will proceed through the abbreviated new drug application pathway for generics under Hatch-Waxman, not through the Biologics Price Competition and Innovation Act.
The relevant risks are generic ertugliflozin, generic fixed-dose ertugliflozin/metformin, therapeutic substitution, payer formulary exclusion, and price compression.
How strong is the commercial outlook for Segluromet?
Segluromet has a moderate near-term commercial profile and a weak long-term exclusivity profile relative to leading SGLT2 franchises.
Its strengths are:
- Established FDA approval.
- Convenient fixed-dose administration.
- Integration with the broader Steglatro franchise.
- Potential use among patients requiring both ertugliflozin and metformin.
- Continued demand for oral type 2 diabetes therapies.
Its weaknesses are:
- Later entry into a crowded SGLT2 market.
- Limited differentiation in cardiovascular and kidney outcomes.
- Generic availability of metformin.
- Dependence on ertugliflozin patent protection.
- Lack of separately disclosed product revenue.
- Potential payer preference for Jardiance and Farxiga.
- Shared patent exposure across the ertugliflozin franchise.
Key Takeaways
- Segluromet is the ertugliflozin/metformin hydrochloride fixed-dose combination marketed by Merck and Pfizer.
- The FDA approved Segluromet in December 2017 under NDA 209806.
- Metformin contributes little patent value; ertugliflozin provides the principal exclusivity.
- The relevant U.S. patent-protection window is expected to extend into approximately 2029 or later, subject to the applicable Orange Book patents and term adjustments.
- The key competitors are Synjardy, Xigduo XR, Jardiance, Farxiga, and Invokana.
- VERTIS-CV established cardiovascular safety but did not give ertugliflozin the same outcome-based commercial position as leading SGLT2 products.
- Pfizer and Merck do not separately disclose Segluromet revenue, preventing a reliable standalone financial-growth calculation.
- Generic risk is expected to rise sharply in the late 2020s.
- Biosimilar competition is irrelevant because ertugliflozin/metformin is a small-molecule product.
- The largest commercial risk is a coordinated loss of exclusivity affecting Steglatro, Segluromet, and Steglujan.
FAQs
Is Segluromet the same as Jardiance?
No. Segluromet contains ertugliflozin and metformin. Jardiance contains empagliflozin and is available separately from metformin-containing products such as Synjardy.
Is metformin hydrochloride still patent protected?
No meaningful molecule-level patent protection remains for metformin hydrochloride. It is widely supplied as a generic drug.
Can a patient take generic metformin with Steglatro instead of Segluromet?
Clinicians may prescribe the components separately when appropriate. This substitution can reduce the commercial value of the fixed-dose combination even before a generic Segluromet product launches.
Will ertugliflozin have biosimilars?
No. Ertugliflozin is a small molecule. Future competitors will be generics approved through the abbreviated new drug application pathway.
Which product has the stronger commercial position, Segluromet or Synjardy?
Synjardy has the stronger commercial position because empagliflozin benefits from broader cardiovascular and heart-failure market recognition. Segluromet remains viable but is more exposed to payer preference and late-entry disadvantages.
References
-
U.S. Food and Drug Administration. (2017). Segluromet prescribing information. FDA.
-
Merck & Co., Inc. (2023). Form 10-K annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Pfizer Inc. (2023). Form 10-K annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and the Hatch-Waxman Act. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gantz, I., VERTIS CV Investigators. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine, 383(15), 1425-1435.
